Pro-Dex, Inc. — Form 10-Q Summary
Reporting period: Fiscal third quarter and nine months ended March 31, 2024; filed May 2, 2024. The filing covers fiscal 2024 Q3, notwithstanding the request metadata’s “2023 Q3.” Financial amounts below are in millions of dollars unless otherwise indicated.
Business context
Pro-Dex designs and manufactures surgical drivers and shavers, primarily for orthopedic, cranio-maxillofacial (CMF), and thoracic markets, and also sells rotary air motors. Revenue is highly dependent on medical-device products, a small number of customers, and repair work for its largest customer.
Financial results and liquidity
| Metric | Three months ended Mar. 31, 2024 | Three months ended Mar. 31, 2023 | Nine months ended Mar. 31, 2024 | Nine months ended Mar. 31, 2023 |
|---|---|---|---|---|
| Net sales | $14.293 | $13.079 | $38.819 | $35.448 |
| Gross profit / margin | $4.002 / 28% | $3.811 / 29% | $10.462 / 27% | $9.390 / 26% |
| Operating income | $2.213 | $2.065 | $4.822 | $4.152 |
| Net income | $0.655 | $1.617 | $0.540 | $5.572 |
| Diluted EPS | $0.19 | $0.45 | $0.15 | $1.52 |
- Quarterly sales rose 9% year over year; nine-month sales rose about 10%. Quarterly operating income improved, but net income fell, principally reflecting a $1.192 million unrealized loss on marketable equity investments versus a $0.242 million unrealized gain in the prior-year quarter. For the nine months, the investment result swung to a $3.785 million loss from a $3.407 million gain.
- Cash from operations was $5.179 million for the nine months, compared with $4.835 million. Cash and cash equivalents were $3.219 million at March 31, 2024. Working capital was $25.538 million; current assets were $35.957 million and current liabilities $10.419 million.
- Investments totaled $6.120 million, including $4.577 million of short-term marketable equity securities. Their reported market value is subject to volatility; management reported $2.2 million of net unrealized gains in the portfolio at period-end.
- Balance-sheet notes payable totaled $11.742 million, alongside $1.299 million of noncurrent lease liabilities. The company had $2.5 million drawn on its amended revolving loan and $4.5 million of availability under the $7.0 million facility. Management said cash, receivables, operating cash flow, potential investment sales, and borrowing capacity were expected to meet needs for at least 12 months.
- Investing cash outflow was $2.126 million, including $1.250 million to exercise the Monogram warrant and $0.876 million for equipment and improvements. Financing cash outflow was $2.770 million, including $1.830 million of share repurchases and net loan principal payments.
Material changes and operating trends
- Medical-device product sales grew 40% in the quarter and 12% year to date. Orthopedic sales, including sales to the largest customer, and thoracic driver sales contributed to growth. CMF sales declined, partly because a distributor was selling legacy inventory.
- Repairs revenue declined 13% in the quarter but increased 25% year to date, reflecting upgrades to the largest customer’s orthopedic handpieces. The prior-year quarter included a $0.520 million compensation adjustment for earlier upgrades that did not recur.
- NRE and prototype revenue fell 76% in the quarter and 68% year to date because fewer customer projects were billable. Gross margin fell about one percentage point in the quarter, mainly due to higher inventory and warranty charges; year-to-date margin improved about one point.
- Customer concentration remains substantial: the largest customer accounted for 75% of quarterly sales and 71% of nine-month sales. The two largest customers together represented 94% of gross receivables at March 31, 2024.
- Backlog was approximately $25.2 million, with $9.9 million scheduled for delivery in fiscal Q4 and the balance in the next fiscal year. Backlog is firm acknowledged purchase orders and excludes some revenue under existing contracts.
Outlook, risks, and unusual items
- No numerical revenue or earnings guidance was provided. Management described plans to develop products, expand manufacturing capacity at its Franklin facility, and pursue new and existing customer opportunities; it cautioned that growth may be uneven and that planned products and revenue are uncertain.
- Management expects research and development investment to increase. The ENT Shaver project is suspended, with no determination whether or when development will resume. A CMF Driver project lists an expected Q1 2025 launch and estimated annual revenue of $0.5 million; these are estimates, not assured outcomes.
- The company reported a continuing material weakness in controls over valuation and disclosure of investments, including Level 2 investments, and concluded disclosure controls and procedures were ineffective as of March 31, 2024. Remediation and monitoring continue.
- Prior-year comparative results were restated for the estimated fair value of the Monogram warrant and associated tax expense. The filing states the warrant was exercised in October 2023 for $1.250 million, in connection with a Monogram supply agreement; the resulting shares are now classified as short-term marketable equity securities. Pro-Dex’s CEO is also a Monogram board member.
- Management cited risks including customer and market concentration, competition, product development and commercialization, manufacturing optimization, and variable order timing. The filing reports no material changes to previously disclosed risk factors and no subsequent events requiring disclosure. It notes potential ordinary-course legal proceedings but does not identify a specific material case.
Most important facts for investors to verify
- Whether customer concentration and the largest customer’s purchase patterns support continued sales and backlog conversion.
- How investment valuations, related-party governance, and the disclosed internal-control material weakness are being addressed.
- Whether investment-price movements will continue to materially affect reported earnings and liquidity.
- Progress, launch timing, and commercial prospects for development projects, as well as the economics of the Franklin facility and battery manufacturing.
- Debt repayment and refinancing terms, covenant compliance, and the availability of revolving credit through its stated maturity.